Source: LexaGene
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • LexaGene (LXG) has shortened the time its MiQLab System needs to report a result
  • The system is designed for in-clinic use and requires less than a minute to initiate sample processing
  • It returns results on the presence of 10 different pathogens and 33 markers for antimicrobial resistance
  • LexaGene is a molecular diagnostics company that has commercialized the MiQLab System for fast and easy detection of pathogens and other molecular markers
  • Lexagene Holdings Inc. (LXG) is up 20.83 per cent, trading at C$0.145 per share at 12:08 pm ET

LexaGene (LXG) has significantly shortened the time its MiQLab System needs to report a result.

The molecular diagnostics company has commercialized the MiQLab System for automated PCR-based syndromic testing in veterinary clinics. The system is designed for in-clinic use and requires less than a minute to initiate sample processing. It returns results on the presence of 10 different pathogens and 33 markers for antimicrobial resistance.

The microfluidic system executes a complex series of scripts to complete three main tasks, namely sample preparation, PCR reaction assembly, and PCR amplification and reporting. These three tasks which used to take 120 minutes to complete, can now be completed in just 80 minutes.

Steve Armstrong, Chief Operating Officer of LexaGene commented on the news.

“LexaGene’s mission has been to provide the highest quality data in the shortest time possible. My team evaluated each of the three tasks and has increased some efficiencies that have shaved 40 minutes off the time required to generate a result. We are completing some additional validation tests before releasing these improvements to our customers. We anticipate this to happen over the next 4-6 weeks.”

Dr. Jack Regan, Founder and CEO of LexaGene also shared his views.

“We’ve heard from our customers about the importance of a fast time-to-result. We are already in a different league from the days it takes to receive culture results, but we wanted to push our system even faster than it currently is. We are excited about these advancements and will continue to push our System to report the fastest test results possible without compromising data integrity.”

LexaGene is a molecular diagnostics company that has commercialized the MiQLab System for fast and easy detection of pathogens and other molecular markers. Its customers include veterinary hospitals, reference laboratories and contract biologic manufacturers.

Lexagene Holdings Inc. (LXG) is up 20.83 per cent, trading at C$0.145 per share at 12:08 pm ET.


More From The Market Herald

" Voyageur (TSXV:VM) completes SmoothX testing

Voyageur Pharmaceuticals (VM) has completed the production test batch of its SmoothX product for the computerized tomography (CT) imaging market in Canada.
Aleafia Health - CEO, Tricia Symmes

" Aleafia Health (TSX:AH) completes TSX review and enters fifth province

Aleafia Health (AH) has completed the TSX delisting review and has satisfied the Toronto Stock Exchange’s requirements for continued listing.

" Alpha Cognition (TSXV:ACOG) withdraws public offering

Alpha Cognition (ACOG) has withdrawn its previously-announced marketed public offering.
Bright Mind Biosciences - CEO, Ian McDonald

" Bright Minds Biosciences (CSE:DRUG) announces non-brokered private placement

Bright Minds Biosciences (DRUG) has announced a non-brokered private placement of gross proceeds of $2,050,000.